Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer
Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Oct 27, 2015
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
Patients who have met all eligibility criteria will be randomized to standard oral hygiene, standard oral hygiene + true acupuncture twice weekly for 4 weeks, or standard oral hygiene + sham acupuncture twice weekly for 4 weeks by a form of adaptive randomization, called minimization, because simple randomization could result in covariate imbalances .
The acupuncture points will be at three sites on each ear (Shenmen, Point Zero, Salivary Gland 2-prime), a site on the chin (CV24), a site on each forearm (Lu7), a site on each hand (LI 1-prime), a site on each leg (K6), and one placebo needl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be at least 18 years of age and able to give informed consent.
- • Must be able to read, write and understand English.
- • Must have a diagnosis of head/neck cancer.
- * Must have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified Radiation Therapy Oncology Group (RTOG) scale:
- • Grade 0 - None
- • Grade 1 - Slight dryness of mouth (good response on stimulation and no significant dietary alterations necessary)
- • Grade 2 - Moderate dryness of mouth (poor response on stimulation and altered oral intake required such as frequent water, oral lubricants, or soft-moist foods)
- • Grade 3 - Complete dryness of mouth (no response on stimulation and difficult oral alimentation; IV fluids, pureed diet or tube feedings may be required)
- • Grade 4 - Fibrosis
- • Must have received external beam radiation at a mean dose of at least 24 Gy to one of the parotid glands. The other gland can receive less than 24 Gy.
- • Must have completed radiotherapy at least 12 months prior to entry.
- • Must have anatomically intact parotid and submandibular glands. A focused (head/neck) history and exam conducted by a physician or dentist within the past year is required.
- • Must be acupuncture naïve.
- • Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Exclusion Criteria:
- • History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation.
- • Suspected or known closure of salivary gland ducts on either side. (Patients addressed in inclusion criteria (i.e. those who have had one submandibular gland removed) are expected to have closure to the removed submandibular gland and will be exempt from this exclusion criteria.)
- • Currently receiving or planning to use drugs, herbs, alternative medicines, or devices that could affect salivary production. Treatment known to affect salivation should be stopped at least 14 days prior to enrollment. Over the counter products used for salivary substitution are allowed, but will need to be discontinued for at least 24 hours prior to saliva and questionnaire data collection.
- • Have received any investigational new drug within the past 30 days or planning to receive such during the study period.
- • Active systemic infection or skin infection at or near the acupuncture sites.
- • Receiving chemotherapy during study period.
About Wake Forest University Health Sciences
Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edina, Minnesota, United States
Houston, Texas, United States
Chillicothe, Ohio, United States
Coon Rapids, Minnesota, United States
Portland, Oregon, United States
Honolulu, Hawaii, United States
Minneapolis, Minnesota, United States
Honolulu, Hawaii, United States
Winston Salem, North Carolina, United States
Saint Louis Park, Minnesota, United States
Albuquerque, New Mexico, United States
Cedar Rapids, Iowa, United States
Nashville, Tennessee, United States
Burbank, California, United States
San Francisco, California, United States
San Jose, California, United States
San Rafael, California, United States
Santa Clara, California, United States
Santa Rosa, California, United States
South San Francisco, California, United States
Walnut Creek, California, United States
Honolulu, Hawaii, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Chicago, Illinois, United States
Cedar Rapids, Iowa, United States
Greenville, South Carolina, United States
Greenville, South Carolina, United States
Boiling Springs, South Carolina, United States
Seneca, South Carolina, United States
Santa Fe, New Mexico, United States
Lacey, Washington, United States
Columbus, Ohio, United States
Conroe, Texas, United States
Houston, Texas, United States
San Rafael, California, United States
Patients applied
Trial Officials
Suzanne C Danhauer, PhD
Principal Investigator
Wake Forest University Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials